Atila Altuntas

Atila Altuntas

Auto-generated profile, based on publicly available information

Atila Altuntas

Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MÖMurat ÖZDEDE
Murat ÖZDEDE
SYSerap Yadigar
Serap Yadigar
AGAlper Tuna Guven
Alper Tuna Guven
SASuat Akgür
Suat Akgür
FAFelemez ARSLAN
Felemez ARSLAN
EBElif Arı Bakır
Elif Arı Bakır
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.

29 January 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
NKNasif Fatih Karakuyu
Nasif Fatih Karakuyu
TCTugce Camlica
Tugce Camlica
HAHalil Asci
Halil Asci
AMAdem MİLLETSEVER
Adem MİLLETSEVER
AUArzu Ulusoy
Arzu Ulusoy
AAAtila Altuntas
Atila Altuntas
The kidneys have a regulatory role in many diseases with their diuresis function and capacity to maintain electrolyte balance. In case of extensive damage, the kidney’s filtration capacity is impaired and cannot fulfill its functions. Fluvoxamine (FLV), an antidepressant agent, has antioxidant and anti-inflammatory effects. This study aimed to investigate the protective effects of FLV against renal tissue damage in the lipopolysaccharide (LPS) induced systemic inflammation model. Thirty-two Wistar Albino rats were divided into four equal groups: control, LPS, LPS + FLV, and FLV alone. Six hours after LPS administration, rats were sacrificed and kidney tissues were removed. Histopathological examination of kidney tissues, immunohistochemical expression of the ACE-1, Cas-9, and interleukin-10 (IL-10), as well as spectrophotometric assessment of total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), urea, creatinine levels, and zonulin-1 (ZO-1), claudin-5 (CL-5), aquaporins 2 and 4 (AQ-2, AQ-4) were evaluated. TOS, OSI, urea, creatinine levels, and Cas-9 expressions were significantly increased, and TAS levels, ACE-1, IL-10, AQ-2, AQ-4, ZO-1, and CL-5 expressions significantly decreased in the LPS group compared with the control group. In addition, marked hyperemia, slight-to-moderate hemorrhages, and degeneration of the tubule epithelial cells were observed in kidney sections in the LPS group, in addition to the inflammatory cell infiltrations. FLV treatment significantly improved all these findings. FLV treatment ameliorates renal tissues against inflammatory scenes and protects renal function by enhancing IL-10 and ACE-1 expressions and preserving AQ-2, AQ-4, CL-5, and ZO-1 expressions. Graphical Abstract

21 March 2026 in SDÜ Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
AAAtila Altuntaş
Atila Altuntaş
BABünyamin Aydın
Bünyamin Aydın
SESiddika Ersoy
Siddika Ersoy
ÖEÖzcan EREL
Özcan EREL
HDHasret Demirel
Hasret Demirel
ŞTŞeniz Tutum
Şeniz Tutum
ObjectiveDiabetic nephropathy (DN) remains one of the mostserious complications of type 2 diabetes mellitus(T2DM). Traditionally, disease progression hasbeen evaluated through albuminuria, yet increasingevidence highlights the role of oxidative stress andredox imbalance in DN pathogenesis. The presentstudy was designed to evaluate dynamic thiol/disulfidehomeostasis across albuminuria stages and to exploreits potential role as a complementary systemic oxidativestress marker alongside albuminuria in T2DM.Material and MethodA total of 122 individuals were included and categorizedinto four study groups: 30 healthy participants (Group1), 31 normoalbuminuric diabetic patients (Group 2),31 patients with microalbuminuria (Group 3), and 30patients with macroalbuminuria (Group 4). Plasmathiol/disulfide parameters were measured using theautomated method developed by Erel and Neselioglu,while urinary albumin concentrations were determinedby immunoturbidimetric assay.ResultsProgressive decreases in both native and total thiollevels were observed with advancing severity ofalbuminuria (p

24 August 2026 in SDÜ SAĞLIK BİLİMLERİ DERGİSİ
Verified
Journal Article
Closed access
AAAtila Altuntaş
Atila Altuntaş
SESiddika Ersoy
Siddika Ersoy
ŞTŞeniz Tutum
Şeniz Tutum
HDHasret Demirel
Hasret Demirel
Introduction: Depression and anxiety are common psychological complications in patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT). The COVID-19 pandemic has further exacerbated the psychological distress experienced by these patients. This study aimed to investigate the anxiety and depression levels of patients receiving RRT during the COVID-19 outbreak and to identify the factors associated with these psychological outcomes.Materials and Methods: This descriptive study was conducted among adult patients who were received peritoneal dialysis or hemodialysis treatment for at least 6 months. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression levels. Demographic and clinical data were also collected.Results: A total of 150 patients participated in the study, with a mean age of 54.3 ± 14.6 years. The majority of patients were male (60.7%) and married (70.7%). The mean HADS anxiety score was 8.9± 4.3, and the mean HADS depression score was 7.9±4.2. The prevalence of anxiety and depression was 44.7% and 38.7%, respectively. Multivariate analysis revealed that female gender, lower education level, and comorbidities were significantly associated with higher anxiety and depression levels.Discussion: The study findings suggest that anxiety and depression are prevalent among patients receiving RRT during the COVID-19 outbreak. Female gender, lower education level, and comorbidities were identified as risk factors for these psychological outcomes. Healthcare providers should be aware of these risk factors and provide appropriate support and interventions to improve the mental well-being of patients with ESRD receiving RRT during the COVID-19 pandemic.

30 June 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AAAtila Altuntas
Atila Altuntas
HAHalil Asci
Halil Asci
İİİlter İlhan
İlter İlhan
SOSefa Alperen Ozturk
Sefa Alperen Ozturk
ESEsra Sirazi
Esra Sirazi
DYDudu Seher Yurt
Dudu Seher Yurt

Verified
Journal Article
Open access
PDF file
AGAlper Tuna Guven
Alper Tuna Guven
SYSerap Yadigar
Serap Yadigar
MÖMurat ÖZDEDE
Murat ÖZDEDE
SASuat Akgür
Suat Akgür
FAFelemez ARSLAN
Felemez ARSLAN
EBElif Arı Bakır
Elif Arı Bakır
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.